Artikel
Bronchoalveolar Lavage Lateral-Flow Device Test For Invasive Pulmonary Aspergillosis In Patients With Hematologic Malignancies And In Solid Organ Transplant Patients: A Multicenter Study
Suche in Medline nach
Autoren
Veröffentlicht: | 19. Mai 2014 |
---|
Gliederung
Text
Timely diagnosis and early intervention with antifungal drugs are key factors in the successful treatment of invasive pulmonary aspergillosis (IPA). Therefore, new diagnostic tests are urgently needed. The Lateral-Flow Device (LFD) test is a rapid (15 min) single sample point-of-care test that is based on the detection of an Aspergillus extracellular glycoprotein antigen by monoclonal antibody JF5. In a multicenter study we evaluated the LFD test by using bronchoalveolar lavage (BAL) samples from patients after solid organ transplantation (SOT) and from patients with hematologic malignancies.
47 BAL samples from 47 SOT patients (11 probable/proven IPA, 11 possible IPA, 25 no IPA) and 74 BAL samples from 74 patients with underlying hematological malignancies (30 probable/proven IPA) were included. Diagnostic accuracy of LFD for probable/proven IPA was evaluated. Participating centers were the three Austrian Medical Universities of Innsbruck, Vienna and Graz and the University Hospital of Mannheim, Germany.
Sensitivity and specificity, positive- and negative predictive value as well as diagnostic odds ratio of BAL LFD tests for probable IPA in patients with SOT and those with hematologic malignancies are depicted in Table 1 [Tab. 1].
To conclude, the LFD test of BAL specimens is performed easily and provides accurate and rapidly available results in patients after SOT as well as in patients with underlying hemato-oncological malignancies. Therefore, this new point-of-care test may be a very promising diagnostic approach for detecting IPA using BAL specimens.